Absci Corp. Reports 2024 Annual Results: Financial Performance and Future Prospects
Absci Corp., a pioneering player in the biotechnology sector specializing in AI-driven drug discovery, has released its annual report for the fiscal year 2024. The report highlights significant advancements in its Integrated Drug Creation platform, alongside a challenging financial landscape marked by substantial operating losses and ongoing investments in research and development.
1. Overview of Absci Corp.
Founded with a mission to revolutionize drug development, Absci Corp. leverages cutting-edge generative AI models to create differentiated antibody therapeutics. The company aims to address hard-to-drug targets in the pharmaceutical landscape, positioning itself as a leader in the biopharmaceutical industry.
Key Highlights from 2024
- Funding Success: In March 2024, Absci successfully closed a public offering of common stock, raising $80.8 million in net proceeds from the sale of 19,205,000 shares at $4.50 per share. This funding is critical for supporting ongoing research and development activities.
- Product Development: Absci is advancing two key development candidates: ABS-101 for Inflammatory Bowel Disease (IBD) and ABS-201 for androgenic alopecia (AGA). The preclinical development of ABS-101 is ongoing, with regulatory filing anticipated in 2025.
2. Financial Performance
Income Statement Overview
Absci's financial performance for the year ending December 31, 2024, reflects significant challenges. The company reported a net loss of $103.1 million, slightly improving from a net loss of $110.5 million in 2023.
- Revenue: The total revenue for 2024 was $4.53 million, a decline from $5.71 million in the previous year. This drop is attributed to increased competition and delays in product development.
- Operating Expenses: Total operating expenses surged to $113.4 million, up from $121.2 million in 2023. The primary drivers of this increase were the company's research and development expenses, which rose by 33% to $63.85 million, underscoring Absci's commitment to innovation.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Net Income | -110.5M | -103.1M |
Profit | -110.5M | -103.1M |
Net Income Continuing | -110.5M | -103.1M |
Income Tax Expense | 100K | 70K |
Pretax Income | -110.4M | -103.0M |
Non-operating Income | 5.04M | 5.85M |
Operating Income | -115.5M | -108.8M |
Revenue | 5.71M | 4.53M |
Costs and Expenses | 121.2M | 113.4M |
Operating Expenses | 121.2M | 113.4M |
Depreciation, Depletion & Amortization | 13.99M | 13.38M |
Impairment Expense | 21.33M | 0 |
Research & Development | 48.06M | 63.85M |
Selling, General & Administrative | 37.83M | 36.17M |
Balance Sheet Analysis
As of December 31, 2024, Absci Corp. reported total assets of $213.6 million, a decrease from $217.2 million in 2023. This decline is largely due to a reduction in cash reserves and investments.
- Assets: Current assets made up $133.8 million of the total, with cash and equivalents totaling $41.21 million. The non-current assets accounted for $79.77 million, reflecting ongoing investments in intangible assets and R&D facilities.
- Liabilities: Total liabilities stood at $34.47 million, consisting primarily of current liabilities of $28.65 million. The company maintains a solid equity base of $179.1 million, although retained earnings remain negative at $-509.6 million.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Total Assets | 217.2M | 213.6M |
Total Current Assets | 120.5M | 133.8M |
Cash and Equivalents | 72.36M | 41.21M |
Restricted Cash and Investments | 16.19M | 15.94M |
Prepaid Expenses | 4.53M | 5.45M |
Other Current Assets | 25.29M | 71.21M |
Total Non-current Assets | 96.72M | 79.77M |
Intangible Assets | 48.25M | 44.88M |
Net PP&E | 41.32M | 29.16M |
Lease Assets | 4.49M | 3.96M |
Other Non-current Assets | 2.64M | 1.75M |
Total Liabilities and Equity | 217.2M | 213.6M |
Total Liabilities | 41.12M | 34.47M |
Total Current Liabilities | 29.55M | 28.65M |
Accounts Payable and Accrued Liabilities | 20.80M | 10.37M |
Current Debt | 5.57M | 4.41M |
Current Deferred Revenue | 3.17M | 1.11M |
Other Current Liabilities | 0 | 12.75M |
Total Non-current Liabilities | 11.56M | 5.81M |
Long-term Debt | 4.73M | 1.25M |
Non-current Deferred Revenue | 966K | 0 |
Non-current Deferred Tax Liabilities | 186K | 0 |
Other Non-current Liabilities | 5.67M | 4.56M |
Total Equity and Non-controlling Interests | 176.1M | 179.1M |
Total Equity | 176.1M | 179.1M |
Cash Flow Insights
Absci Corp. experienced a net change in cash of $-31.45 million for the year, primarily driven by cash outflows from operating activities totaling $72.4 million. The company reported a robust financing activity, generating $82.52 million through equity offerings.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Net Change in Cash | 12.82M | -31.45M |
Net Cash from Operating Activities | -64.63M | -72.40M |
Operating Profit | -110.5M | -103.1M |
Adjustment to Operating Profit | 45.93M | 30.70M |
Net Cash from Investing Activities | 81.94M | -41.57M |
Investments | -82.55M | 42.11M |
Productive Assets | 606K | -535K |
Net Cash from Financing Activities | -4.48M | 82.52M |
Debt | -5.34M | -4.03M |
Equity Issuance/Repurchase | 862K | 86.55M |
3. Strategic Developments
Research and Development Focus
Absci's commitment to R&D is evident in its increased expenditure aimed at enhancing its drug development capabilities. The company is aware of the lengthy and costly processes associated with traditional drug development, emphasizing its AI-driven approach to reduce time and costs significantly.
Collaborations and Partnerships
In 2024, Absci announced collaborations with notable institutions, including a partnership with a global cancer center to leverage generative AI for novel therapeutic discoveries. These partnerships are vital for expanding Absci’s research capabilities and enhancing its product pipeline.
4. Future Outlook
As Absci Corp. navigates the complexities of the biotechnology landscape, the company's leadership is optimistic about its long-term prospects. The anticipated regulatory filings and the potential for successful product launches in the coming years may provide a pathway to profitability.
Conclusion
Despite facing financial headwinds and operational challenges, Absci Corp. remains committed to its mission of transforming drug discovery through innovative AI technologies. With a robust pipeline and strategic collaborations, the company is positioned to lead the next generation of biopharmaceutical advancements. Investors and stakeholders will be closely watching how the company leverages its capabilities to overcome current challenges and achieve its ambitious goals in the years to come.
